CELG News and Press, Celgene Corporation From 12/30/19

One of my better results in 2019 has been by buying into Celgene( CELG ) which was being acquired by ( BMY ). In that transaction, Celgene shareholders received a contingent value right or CVR which has been underestimated by the market from day one. It continues to be undervalued. The right t...

2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Phas...

On Nov. 20, Bristol-Myers Squibb (NYSE: BMY) announced the completion of its $74 billion acquisition of Celgene  (NASDAQ: CELG) . Bristol-Myers' strategy centers on merging an innovative, agile biotechnology company with the reach and resources of a major pharmaceutical company. ...

GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that Sol Barer, PhD has been appointed as the Company&...

Have you Noticed All the Merger Announcements? I Have A feature of this stock market has been accelerated merger announcements. I don’t believe we are at historic levels but I see it accelerating recently. I have said this many times recently, the fact that M&A is going on mea...

In the middle of November, Editas Medicine (NASDAQ: EDIT) and Celgene (NASDAQ: CELG) announced changes to a development pact originally formed in 2015 with Juno Therapeutics, which is now part of Celgene. The agreement was amended in 2018, too, so the fact that changes were made wasn't n...

Shares of Editas Medicine (NASDAQ: EDIT) rose more than 45% last month, according to data from  S&P Global Market Intelligence . The gene editing pioneer rose for reasons both internal and external.  The business announced an amended collaboration with Celgene (NASDAQ: CELG...

This article is part of a series that provides an ongoing analysis of the changes made to David Abrams' 13F portfolio on a quarterly basis. It is based on Abrams' regulatory 13F Form filed on 11/14/2019. Please visit our Tracking David Abrams' Abrams Capital Management article for an idea ...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...

Merger activity decreased, with three new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Carolina Financial Corporation (CARO) by United Bankshares (UBSI) for $1.1 billion in an all-stock deal. Under the terms of the agreement, United will...